HOME >> BIOLOGY >> NEWS
Virginia Bioinformatics Institute to develop Tomato Metabolite Database

Blacksburg, Va. A researcher at the Virginia Bioinformatics Institute (VBI) at Virginia Tech is developing a database and computational tools to help scientists learn more about how certain genes in tomatoes affect the crop's flavor and nutritional value.

The Tomato Metabolite Database, which is being implemented by Zhangjun Fei, a senior bioinformatics scientist in VBI's Cyberinfrastructure Group, will be used to store a wide range of information and data about tomato, including microarray and metabolite profiling data as well as information on metabolic pathways. This resource will be used to identify key genes involved in the synthesis of essential metabolites that impact tomato flavor and the quality of its nutrients.

Fei's work is part of a collaboration with Harry Klee, professor of horticultural science at the University of Florida and principal investigator for the project, and Jim Giovannoni, adjunct professor of plant biology at the Boyce Thompson Institute at Cornell University and research molecular biologist at the United States Department of Agriculture (USDA) Agricultural Research Service's Plant, Soil and Nutrition Laboratory. The work is funded by a $2-million grant from the National Science Foundation.

Research groups led by Klee and Giovannoni will use the information provided by the Tomato Metabolite Database to characterize the functions of those genes identified as being responsible for genetic variation in tomato using state-of-the-art RNA interference (RNAi) technology. RNAi technology allows scientists to silence or turn down the specific function of a gene within a cell and represents a powerful approach to accurately establish gene function on a large scale.

"The development of this database will allow researchers the world over to develop and test hypotheses regarding the regulation of flavor, nutrition and quality metabolites in edible crop tissues," said Klee.

By identifying the highly complex
'"/>

Contact: Susan Bland
subland@vbi.vt.edu
540-231-7912
Virginia Tech
6-Apr-2006


Page: 1 2

Related biology news :

1. Virginia Tech researchers to study poplar tree as model biomass crop
2. Fire ants are emerging nuisance for Virginians
3. Virginia Techs System X supercomputer provides super tool for simulation of cell division
4. Asian Soybean Rust found in Virginia, but not a threat to current crop
5. Virginia Tech chemists create new polymers by adding DNA base pairs
6. Pregnant drivers, football players safer thanks to a top Virginia Tech researcher
7. Virginia Tech student selected to meet Nobel Laureates
8. Virginia study urges early emphasis on science
9. Award supports Virginia Tech research to reduce vehicle emissions, create biofuel
10. Oswaldo Cruz Foundation, Virginia Bioinformatics Institute sign agreement...
11. Virginia Tech to host Biodiversity Conservation in Agriculture Symposium

Post Your Comments:
(Date:3/11/2015)... , March 11, 2015   The ... its platform to scientifically measure and harness music ... to real-time biometrics and objective measurements of physiology, ... music at scale in large populations. It is ... technologists and clinicians perform rigorous studies and accelerate ...
(Date:3/10/2015)... 2015  NXT-ID, Inc. (NASDAQ: NXTD ... biometric authentication company focused on the growing mobile ... has been named the "Number One Best Tech ... Rethink Modern ( http://www.rethinkmodern.com/ ) is a web ... and lifestyle that have a unique function or design.  ...
(Date:3/2/2015)... SAN JOSE, Calif. , March 2, 2015 ... ), the leading developer of human interface solutions, ... ID technology that is designed to enable rapid ... Synaptics Natural ID™ module for gaming is a ... and ODMs the ability to quickly integrate fingerprint ...
Breaking Biology News(10 mins):Introducing The Sync Project, a Global Collaboration Harnessing the Scientific Potential of Music for Health 2Introducing The Sync Project, a Global Collaboration Harnessing the Scientific Potential of Music for Health 3NXT-ID's Wocket Smart Wallet Named Number One Best Tech Gift for 2015 by Rethink Modern 2NXT-ID's Wocket Smart Wallet Named Number One Best Tech Gift for 2015 by Rethink Modern 3NXT-ID's Wocket Smart Wallet Named Number One Best Tech Gift for 2015 by Rethink Modern 4Synaptics Unveils New Fingerprint ID Solution for Gamers 2Synaptics Unveils New Fingerprint ID Solution for Gamers 3
(Date:3/30/2015)... , March 30, 2015 CASI Pharmaceuticals, Inc. ... the acquisition, development and commercialization of innovative therapeutics addressing ... market with a commercial focus on China ... Drug Administration (CFDA) has approved the Company,s application to ... clear cell carcinoma (OCCC) patients for its proprietary drug ...
(Date:3/30/2015)... GERMANTOWN, Md. , March 30, 2015  /PRNewswire/ ... a leader in synthetic biology, and Merck Serono, ... Germany , today announced an exclusive ... commercialize Chimeric Antigen Receptor T-cell (CAR-T) cancer therapies. ... to develop innovative therapies that modulate the immune ...
(Date:3/30/2015)... Washington, USA (PRWEB) March 29, 2015 ... and the United States and plenary talks by four ... SPIE Optics + Optoelectronics next month in ... technical presentations in 17 conferences alongside a two-day exhibition. ... and photonics , the event will run 13-16 April ...
(Date:3/30/2015)... 2015  Naldemedine, an investigational peripherally acting mu-opioid ... Co., Ltd., met its primary and secondary endpoints ... the treatment of opioid-induced constipation (OIC) in adult ... Study results showed that naldemedine (0.2 mg tablet ... of spontaneous bowel movement (SBM) compared with placebo ...
Breaking Biology Technology:CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 2CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 3CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 4CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 5Intrexon and Merck Serono Announce Agreement for the Development and Commercialization of CAR-T Therapy 2Intrexon and Merck Serono Announce Agreement for the Development and Commercialization of CAR-T Therapy 3Intrexon and Merck Serono Announce Agreement for the Development and Commercialization of CAR-T Therapy 4Laser Energy Advances Among Reports Set for SPIE Optics + Optoelectronics 2Laser Energy Advances Among Reports Set for SPIE Optics + Optoelectronics 3Shionogi & Co., Ltd. Announces That Naldemedine Meets Primary Endpoint In A Phase 3 Study For The Treatment Of Opioid-Induced Constipation 2Shionogi & Co., Ltd. Announces That Naldemedine Meets Primary Endpoint In A Phase 3 Study For The Treatment Of Opioid-Induced Constipation 3
Cached News: